Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30998248 | 0.84 | FFAR1 (0.41) | FFAR1EGLN1HDAC8PARP1ALDH1A1 | |
| SCHEMBL19260416 | 0.80 | FFAR1 (0.39) | FFAR1EGLN1ACACB | |
| SCHEMBL450944 | 0.79 | NOTUM (0.45) | FFAR1ALDH1A1NOTUMEGLN2 | |
| SCHEMBL22031755 | 0.79 | FFAR1 (0.33) | FFAR1EGLN1HDAC8KEAP1EGLN2 | |
| SCHEMBL31098105 | 0.79 | CCR1 (0.35) | FFAR1CCR1EGLN1HDAC8KEAP1 | |
| SCHEMBL15491230 | 0.79 | HDAC8 (0.33) | FFAR1EGLN1HDAC8PARP1KEAP1 | |
| SCHEMBL503728 | 0.79 | CYP1A2 (0.34) | FFAR1EGLN1HDAC8PARP1KEAP1 | |
| SCHEMBL22031495 | 0.79 | CCR1 (0.35) | FFAR1CCR1EGLN1HDAC8KEAP1 | |
| SCHEMBL19113961 | 0.76 | FFAR1 (0.38) | FFAR1HDAC8KEAP1ACACB | |
| SCHEMBL503735 | 0.76 | HRH1 (0.42) | FFAR1HDAC8PARP1KEAP1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2023-07-13 | — | — | US | disclosed |
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4143172-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | Syddansk Universitet (DK) | 2023-03-08 | — | — | EP | disclosed |
| CN-115720579-A | Antibacterial and antifungal pleuromutilin conjugates | 赛丹思科大学 | 2023-02-28 | — | — | CN | disclosed |
| US-20220135557-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| WO-2021219813-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | SYDDANSK UNIVERSITET (DK) | 2021-11-04 | — | — | WO | disclosed |
| EP-3891149-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| CN-111285873-A | RET inhibitors, pharmaceutical compositions thereof and uses thereof | 广东东阳光药业有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2020114487-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135557-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, REL, SLC10A2 | FFAR1 778/4885CCR1 1349/4885EGLN1 3930/4885 |
| US-20230219964-A1 | ANTIBACTERIAL AND ANTIFUNGAL PLEUROMUTILIN CONJUGATES | HDAC6, Q6ZSR9, MON2 | FFAR1 2740/4885CCR1 2176/4885EGLN1 1660/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | FFAR1 202/4885CCR1 542/4885EGLN1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.